Curis stock fell 19.86 percent on October 16, 2026 to USD 0.41
Published on 10/17/2026 at 20:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPrice move and reporting date
- Curis is scheduled to report third-quarter results on November 5, 2026.
- Curis stock traded between USD 0.33 and USD 33.60 over the past 52 weeks.
- Curis stock stood at USD 0.41 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 19.86 percent from the prior close.
- Curis recorded 1,318,473 shares in trading volume on October 16, 2026.
Curis stock fell 19.86 percent to USD 0.41 on Nasdaq on October 16, 2026, its latest completed session. MarketBeat lists November 5, 2026 as the estimated date for the company's third-quarter report. Curis stock last stood at USD 0.41 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 19.86 percent from the prior close.
Cash position shapes the picture
Curis reported a consolidated net loss of USD 8.58 million for the second quarter ended June 30, 2026. Operating loss reached USD 9.94 million for the same period, while operating cash flow was negative USD 9.65 million. The company held USD 5.07 million in cash at June 30, 2026.
Curis is a biotechnology company developing cancer therapies, with emavusertib as its lead investigational program, according to the company's investor-relations page. The company describes emavusertib as an oral IRAK4 and FLT3 inhibitor. The next scheduled report gives investors a defined date for the next financial update.
Yearly range remains wide
The Nasdaq quote stood within a 52-week range of USD 0.33 to USD 33.60 on October 16, 2026. The latest price was USD 0.08, or 24.24 percent, above the 52-week low and USD 33.19, or 98.78 percent, below the 52-week high. Trading volume reached 1,318,473 shares, compared with an average of 230,520 shares.
Comparison with peers
Curis (Nasdaq, USD): minus 19.86 percent, P/E -0.03.
Acrivon Therapeutics (Nasdaq, USD): minus 6.82 percent, P/E -0.87, market capitalization USD 70.3 million.
Sangamo Therapeutics (OTC, USD): minus 21.99 percent, market capitalization USD 45.6 million.
What comes next
The November 5, 2026 report is the next scheduled corporate date identified for Curis. MarketBeat lists an expected consensus of USD -2.29 earnings per share and USD 1.00 million in revenue for the third quarter, compared with USD -9.80 earnings per share and USD 3.18 million in revenue in the year-earlier quarter. The estimate is explicitly presented as a forecast and may change.
Price and scheduled report
Curis ended its latest Nasdaq session at USD 0.41 on October 16, 2026 at 4:00 p.m. ET. The move was down 19.86 percent from the prior close, while the broad 52-week range places the stock near its lower end.
Market context: Market report S&P 500.
